Trial Details
RECRUITINGBasic Information
| Clinical ID | c2648 |
|---|---|
| Identifier | NCT03167437 |
| Trial Title | An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab |
| Trial URL | Visit Original Page |
Study Information
| Study Results | NO |
|---|---|
| Conditions | Crohn's Disease |
| Interventions | DRUG: Vorinostat|DRUG: Ustekinumab |
Participant Information
| Sponsor | National Institute of Allergy and Infectious Diseases (NIAID) |
|---|---|
| City | Bethesda |
| Country/Region | United States |
Enrollment Criteria
| Sex Requirement | ALL |
|---|---|
| Age Requirement | ADULT, OLDER_ADULT |
Study Design
| Study Type | INTERVENTIONAL |
|---|---|
| Phase | PHASE1|PHASE2 |
Time Information
| Start Date | 2017-10-30 |
|---|---|
| Primary Completion Date | 2026-06-30 |
| Completion Date | 2026-06-30 |